AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17082219
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiotherapy plus endocrine therapy
Trial: 9162292
Drug: Bemitil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemitil (0.5 g)
Trial: 9235216
Drug: Phenibut (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenibut (0.25 g)
Trial: 3753670
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg nifalatide
Trial: 3753670
Drug: 48 mg
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mg nifalatide
Trial: 31915163
Drug: Adjunctive azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive azithromycin
Trial: 30721208
Drug: Aflibercept administered
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept administered as 1 injection every other month after 3 initial monthly doses
Trial: 27458584
Drug: Aprepitant (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant (40 mg) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Trial: 27458584
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg IV) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Trial: 12953801
Drug: Palatinose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palatinose (5 g)
Trial: 28612237
Drug: L-thyroxine
RxNorm normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-thyroxine
Trial: 1565347
Drug: Quartered 20-mg
RxNorm normalized name: Quarter Mate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartered 20-mg PGE2 suppository
Trial: 12091845
Drug: Albuterol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (400 microg) nebulization, repeated every 2 hours until potassium level fell below 5 mmol/L (maximum 12 doses)
Trial: 10890262
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium 2% ophthalmic solution BID
Trial: 10890262
Drug: Terfenadine 60-mg
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60-mg tablets BID
Trial: 7724098
Drug: Intravaginal prostaglandin
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal prostaglandin E2 (PGE2) suppositories
Trial: 7724098
Drug: Intramuscular 15-methyl-prostaglandin
RxNorm normalized name: 15(S)-15-Methyl Prostaglandin F2α
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 15-methyl-prostaglandin F2 alpha (15M-PGF2 alpha)
Trial: 31301621
Drug: Supported self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported self-help preventive cognitive therapy (S-PCT)
Trial: 17265038
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo IV (up to 3 injections at least 5 min apart)
Trial: 10518857
Drug: Type-A zeolite
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Type-A zeolite mouthrinse (placebo), rinsed twice a day for five days
Trial: 8129004
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 400 mg of sparfloxacin
Trial: 8129004
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily oral doses totaling 1,000 mg of sparfloxacin
Trial: 22123970
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support from female partner or close female friend during preparation for a stressful task
Trial: 22123970
Drug: No social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No social support during preparation for a stressful task
Trial: 17425628
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg taken 15 min before a high-fat meal (fed)
Trial: 15206668
Drug: Racemic citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic citalopram (20 mg)
Trial: 10023285
Drug: Intra-articular ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular ketorolac 5 mg
Trial: 7485885
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac 10 mg
Trial: 9106379
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diphenhydramine
Trial: 31618678
Drug: 6 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 days of oral flucloxacillin
Trial: 31618678
Drug: Modified cure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified cure assessment for 6 days of therapy
Trial: 31618678
Drug: Modified cure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified cure assessment for 12 days of therapy
Trial: 30551654
Drug: L. rhamnosus
RxNorm normalized name: L. reuteri/L. rhamnosus 1 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. rhamnosus 19070‐2 and L. reuteri 12246 with 250 × 10⁶ CFU, 3.33 mg of fructooligosaccharide, and 200 IU of vitamin D₃ (probiotic group)
Trial: 27798661
Drug: Postoperative treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatments for cancer
Trial: 24916558
Drug: Preworkout supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preworkout supplement (SUP) containing caffeine, creatine, β-alanine, amino acids, and B vitamins, ingested daily for 28 days.
Trial: 24916558
Drug: Preworkout supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preworkout supplement (SUP)
Trial: 23149797
Drug: Continuously variable
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuously variable dose rate (CVDR)
Trial: 20855397
Drug: Day care
RxNorm normalized name: CVS Everyday Care Probiotic Vegetable Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day care management with antibiotic treatment, feeding, and supportive care from 8:00 am to 5:00 pm.
Trial: 20855397
Drug: Hospital care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital care management with similar 24-hour treatment.
Trial: 12870164
Drug: High-dose Caiapo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Caiapo (4 g/d)
Trial: 12870164
Drug: Low-dose Caiapo
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Caiapo (2 g/d)
Trial: 9109825
Drug: Two-solution rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-solution rinse
Trial: 25977313
Drug: Fenoldopam (D1-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (D1-like receptor agonist) during low NaCl diet
Trial: 25977313
Drug: Fenoldopam with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam with enalapril (ACE inhibitor) during low NaCl diet
Trial: 18795988
Drug: 25 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/wk testosterone enanthate
Trial: 18795988
Drug: 50 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/wk testosterone enanthate
Trial: 18795988
Drug: 125 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/wk testosterone enanthate
Trial: 18795988
Drug: 300 mg/wk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/wk testosterone enanthate
Trial: 16374438
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic lock solution (cefazolin 10 mg/ml, gentamicin 5 mg/ml, heparin 1000 U/ml)
Trial: 16374438
Drug: Heparin lock
RxNorm normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin lock solution (heparin 1000 U/ml)
Trial: 16374438
Drug: Heparin lock
RxNorm normalized name: Heparin Lock Flush
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin lock solution
Trial: 16374438
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic lock solution
Trial: 12749507
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg orally once daily
Trial: 12749507
Drug: Fenofibrate 67
RxNorm normalized name: fenofibrate 67 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 67 mg orally TID
Trial: 24139613
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy
Trial: 27028913
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (Vivitrol) for 24 weeks
Trial: 24953333
Drug: Gefitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib monotherapy (250 mg/day)
Trial: 15499696
Drug: Gefitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib monotherapy
Trial: 22762856
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (571-mg metformin acetate)
Trial: 22762856
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (500-mg metformin hydrochloride)
Trial: 11061280
Drug: Prednisone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (20 mg daily for 4 weeks, then 10 mg daily for 1 year, followed by gradual withdrawal over 16 weeks)
Trial: 9314342
Drug: House dust
RxNorm normalized name: House dust
DrugBank: House dust (DB10345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: House dust mite avoidance treatment (Acarosan applied to floors, impermeable covers for mattresses and bedding)
Trial: 29745073
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of colloid (10mg/kg) and crystalloid solutions
Trial: 29745073
Drug: Crystalloid solutions
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid solutions only
Trial: 27917214
Drug: Treadmill walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill walking exercise training for six months in addition to medical treatment
Trial: 18671874
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment in infants (IPTi)
Trial: 3852899
Drug: Sulbenicillin (SBPC)
RxNorm normalized name: sulbenicillin
DrugBank: Sulbenicillin (DB13693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbenicillin (SBPC) 2 g administered intravenously twice a day for 7 days
Trial: 29097028
Drug: actoxumab 10
RxNorm normalized name: Actoxumab
DrugBank: Actoxumab (DB16376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: actoxumab 10 mg/kg + bezlotoxumab 10 mg/kg
Trial: 18162446
Drug: Levocetirizine (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (5mg oral administration)
Trial: 14518696
Drug: Enfuvirtide (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (45 mg, 67.5 mg, or 90 mg twice daily) with background ARV regimen
Trial: 14518696
Drug: Enfuvirtide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (all doses)
Trial: 10996576
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin nasal spray 100 IU
Trial: 10996576
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin nasal spray 400 IU
Trial: 10996576
Drug: Salmon calcitonin
RxNorm normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon calcitonin nasal spray (all active treatment groups)
Trial: 9165960
Drug: rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg.kg‐1
Trial: 1672803
Drug: vecuronium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vecuronium 0.1 mg.kg‐1
Trial: 3541420
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg isosorbide‐5‐mononitrate
Trial: 3541420
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg isosorbide‐5‐mononitrate
Trial: 3541420
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg isosorbide‐5‐mononitrate
Trial: 9046389
Drug: 0.25 g
RxNorm normalized name: AMICAR 0.25 GM/mL Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 g of ethanol/kg of body weight
Trial: 9046389
Drug: 0.50 g
RxNorm normalized name: SALICYLIC ACID 0.50 g in 100 g TOPICAL SOAP [ORIPAN GOLD 100g]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50 g of ethanol/kg of body weight
Trial: 8803645
Drug: Intravenous flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous flumazenil
Trial: 24105303
Drug: Hypothermia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermia group (loading dose of 4°C cold saline, cooled to 32°C to 34°C for 48 hours)
Trial: 21176107
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) using reticulated open‐cell foam (ROCF)
Trial: 12697591
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia (thiopental 5 mg kg(‐1), fentanyl 3 micro g kg(‐1), vecuronium 0.08 mg kg(‐1))
Trial: 19152909
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation (fluid restriction then nothing by mouth 12 hours before the procedure, water and simethicone at capsule ingestion)
Trial: 19152909
Drug: Standard preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preparation + 10 mg oral metoclopramide before the procedure
Trial: 19152909
Drug: Citramag +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citramag + senna + 10 mg metoclopramide before the procedure
Trial: 15891596
Drug: Prokinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic therapy with cisapride (10 mg t.i.d.) after 4 weeks
Trial: 3292844
Drug: Intra-vaginal suppositories
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-vaginal suppositories containing S. nigrescens maceration
Trial: 3292844
Drug: Nystatin suppositories
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nystatin suppositories
Trial: 29995693
Drug: Concurrent exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent exercise (CEX) including 2 aerobic and 9 resistance exercises performed alternately in circuit order for 40 minutes at 60-70% heart rate reserve using body mass or fixed loads.
Trial: 26189007
Drug: Imatinib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 200 mg single dose
Trial: 18608522
Drug: Diane35 (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane35 (35 microg ethinyl estradiol plus 2 mg cyproterone acetate)
Trial: 18608522
Drug: Diane35 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane35 and Diane35/metformin
Trial: 12460869
Drug: urapidil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil (10 mg IC)
Trial: 12460869
Drug: yohimbine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine (3 mg IC)
Trial: 7102537
Drug: Pindolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (5 mg four times a day)
Trial: 12126265
Drug: Nebivolol 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 2.5-5 mg daily (n = 81)
Trial: 12126265
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg daily (n = 87)
Trial: 7697845
Drug: High-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose aspirin (1000 mg/d)
Trial: 1071668
Drug: Alprenolol (200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (200-400 mg, twice daily)
Trial: 22968811
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of both drugs
Trial: 8216696
Drug: Clomipramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (25 to 75 mg)
Trial: 3549811
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% minoxidil
Trial: 3549811
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil (1% and 5%)
Trial: 19601782
Drug: PEG‐IFN (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN (1.5 mcg/Kg/w) plus RBV (>=10.6 mg/kg/d) for 24-48 or 48-72 weeks depending on genotype
Trial: 17617285
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) 1 mg
Trial: 17617285
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) 1 mg to 2 mg
Trial: 17617285
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) 1 mg to 4 mg
Trial: 17617285
Drug: Guanfacine extended-release
RxNorm normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guanfacine extended-release (GXR) 2 mg to 4 mg
Trial: 17617285
Drug: Treatment-emergent adverse
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent adverse events (AEs)
Trial: 11075768
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of vitamin K orally
Trial: 1358233
Drug: Thymoxamine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoxamine (80 mg)
Trial: 23350812
Drug: Inhaled apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled apomorphine 0.2 mg
Trial: 21080144
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and fluoxetine
Trial: 16584394
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction (CIFN 27->9 microg daily for 24 weeks, 9 microg t.i.w. for 24 weeks) with ribavirin 800 mg/day
Trial: 16584394
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment (CIFN 18 microg t.i.w. for 12 weeks, 9 microg t.i.w. for 36 weeks) with ribavirin 800 mg/day
Trial: 16584394
Drug: High-dose induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose induction
Trial: 16584394
Drug: Low-dose treatment
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose treatment
Trial: 30545420
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy intervention (MTG), 30-45 minutes weekly sessions, average of 7 sessions
Trial: 27522631
Drug: Placebo (or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (or continued low-dose spironolactone)
Trial: 20171415
Drug: Pancrelipase delayed-release
RxNorm normalized name: Pancrelipase Delayed-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrelipase delayed-release 12,000-lipase unit capsules
Trial: 11035615
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy with granulocyte-colony-stimulating factor (G-CSF)
Trial: 1623569
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (7.5% NaCl solution)
Trial: 27709794
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg orally)
Trial: 17967675
Drug: placebo (IV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (IV) twice daily (n = 203)
Trial: 2979239
Drug: Trimoprostil (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimoprostil (3 mg b.d.)
Trial: 28764753
Drug: Complex intervention
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex intervention involving training videos and a template for conducting an individualised structured medication review.
Trial: 24440473
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy with concomitant chemotherapy (fluorouracil 350 mg/m² per day intravenous bolus and folinic acid 20 mg/m² per day intravenous bolus)